Table 6 Univariable analysis in the general ward patients after matching
From: Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China
General ward | |||
|---|---|---|---|
Case group (n = 2) | Control group (n = 8) | P | |
Age, years, mean ± SD | 59.23 ± 2.66 | 59.60 ± 2.30 | – |
Sex, n (%) | – | ||
Male | 2 | 8 | |
Female | 0 | 0 | |
Infectious disease/trauma/surgery history, n (%) | 0 | 4 | 0.124 |
Food and drug allergy history, n (%) | 0 | 0 | – |
Allergic disease history, n (%) | 0 | 0 | – |
Other disease, n (%) | 1 | 4 | 1 |
Combined with other drugs, n (%) | 2 | 0 | 0.002 |